Metraipolis › archive › dc_bc76f54bb927

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL — Europe PMC PMID:42495620

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42495620
DOI
10.3389/fimmu.2026.1714145
License (as archived)
solo-consultazione
Archived
2026-10-18T09:39:16.058Z
SHA-256 of the archived text
93fb49110e42115defaaa470699155c3797536d2360e7aaa7ab16dc7d50e130e
Stable URL of this page
https://metraipolis.com/documento/dc_bc76f54bb927

How to cite

Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL — Europe PMC PMID:42495620 — Europe PMC (en), https://europepmc.org/article/MED/42495620 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bc76f54bb927 (Metraipolis archive dc_bc76f54bb927, sha256 93fb49110e42115defaaa470699155c3797536d2360e7aaa7ab16dc7d50e130e)
BibTeX
@misc{dcbc76f54bb927,
  title = {Efficacy-safety trade-off and patient selection: a meta-analysis informing clinical choice between CAR-T and bispecific antibodies for R/R B-NHL — Europe PMC PMID:42495620},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42495620},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bc76f54bb927; sha256 93fb49110e42115defaaa470699155c3797536d2360e7aaa7ab16dc7d50e130e},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42495620. Agents can read the archived copy with the MCP tool read_document.